Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib in previously treated CLL/SLL and NHL
NCT03740529Phase 2Completed
- Sponsor
- Loxo Oncology
- Start
- Mar 2019
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label trial of pirtobrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), non-Hodgkin lymphoma (NHL) and 3 more (11 arms), sponsored by Loxo Oncology. Primary endpoints: Maximum Tolerated Dose at 24 months, Recommended Phase 2 Dose at 24 months and 2 more. Started Mar 2019; status: completed.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)non-Hodgkin lymphoma (NHL)Waldenstrom macroglobulinemia (WM)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03740529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03740529.